Nivolumab treatment in melanoma patients has manageable safety profile

Posted on by admin

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Medical researchers have presented data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients.


SOURCE: Top Health News — ScienceDaily – Read entire story here.

Related posts:

  1. Queensland becomes home to first all-Australian skeleton library A university in Brisbane opens the first all-Australian skeleton library in the country allowing students to study a 'typical Aussie' skeleton. ...
  2. Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015 CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill. ...
  3. Smoking legislation prevents more than 11,000 child hospital admissions in England each year The introduction of smoke-free legislation in England was associated with over 11,000 fewer admissions to hospital a year from respiratory infections in children, according to a new study. ...
  4. Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability. ...
  5. Human Hendra drug, treatment not prevention In a world first in the battle against the deadly Hendra virus, volunteers are being recruited to trial a human treatment for the virus. ...

Related Posts

Risky Business: New York City’s Experience With Fear-Based Public Health Campaigns [Public Health Campaigns]

Fear-based public health campaigns have been the subject of an intense moral and empirical debate. We examined how New York City, under Mayor Michael Bloomberg, used fear-based appeals to confront three challenges to public health: high rates of tobacco use, obesity, and HIV infection. New York City’s use of this type of messaging may have set a precedent. Other state and local health departments will have to navigate how and whether to use fear in a context where it is possible to assert that it can serve the interests of public health. But this will not reduce the need to carefully balance efficacy, uncertainty, stigma, marginalization, emotional burdens, justice, community participation, and scientific credibility.